Who are ICP-488's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inrebic, Tavalisse, Ofev, PONATINIB HYDROCHLORIDE, Sutent, Sunitinib Malate (SU011248).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/icp-488.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ICP-488 — Competitive Intelligence Brief

ICP-488 (ICP-488) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FLT3 inhibitor. Area: Oncology.

phase 3 FLT3 inhibitor FLT3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ICP-488 (ICP-488) — Beijing InnoCare Pharma Tech Co., Ltd.. ICP-488 is a tyrosine kinase inhibitor that targets FLT3 and other kinases involved in hematologic malignancies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ICP-488 TARGET	ICP-488	Beijing InnoCare Pharma Tech Co., Ltd.	phase 3	FLT3 inhibitor	FLT3
Inrebic	FEDRATINIB HYDROCHLORIDE	Bristol-Myers Squibb	marketed		JAK2, FLT3	2019-01-01
Tavalisse	FOSTAMATINIB	Rigel Pharms	marketed		Receptor-type tyrosine-protein kinase FLT3	2018-01-01
Ofev	NINTEDANIB	Boehringer Ingelheim	marketed	Kinase Inhibitor	Receptor-type tyrosine-protein kinase FLT3	2014-01-01
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
Sutent	Sunitinib Malate	Pfizer	marketed	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01
Sunitinib Malate (SU011248)	Sunitinib Malate (SU011248)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3

Recent regulatory actions (last 90 days)

2026-04-02 — Ofev · FDA · approved · US · Boehringer Ingelheim
2026-04-02 — Ofev · FDA · approved · US · Boehringer Ingelheim
2026-04-02 — Ofev · FDA · approved · US · Boehringer Ingelheim
2026-04-02 — Ofev · FDA · approved · US · Boehringer Ingelheim
2026-04-02 — Ofev · MOH · likely_approved · IL · Boehringer Ingelheim
2026-04-02 — Ofev · HSA · likely_approved · SG · Boehringer Ingelheim
2026-04-02 — Ofev · SFDA · likely_approved · SA · Boehringer Ingelheim
2026-04-02 — Ofev · MOH · likely_approved · AE · Boehringer Ingelheim
2026-04-02 — Ofev · MFDS · likely_approved · KR · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FLT3 inhibitor class)

Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Cogent Biosciences, Inc. · 1 drug in this class
Technische Universität Dresden · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ICP-488 — Competitive Intelligence Brief. https://druglandscape.com/ci/icp-488. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab